In the battle against cancer, traditional treatment methods in India often rely on a one-size-fits-all approach, categorizing therapies by the type and stage of cancer. In contrast, Western nations are utilizing advanced genomic research to tailor treatments to the specific molecular characteristics of each cancer case, leading to higher recovery rates. Recognizing the need for a similar shift in India, Hitesh Goswami and Kshitij Rishi established the oncology precision startup 4baseCare in Bengaluru in 2018. Recently, the startup gained significant momentum with an investment of almost $1 million from the Infosys Innovation Fund and a $6 million Series A funding round led by Yali Capital.

Advancements in Targeted Genetic Treatments

During an exclusive interview, 4baseCare's co-founder and CEO, Goswami, elaborated on their innovative approach to cancer treatment. Historically, treatments were uniform, based solely on generalized classifications of cancer types and stages. However, Goswami emphasized that patients with lung cancer, for instance, are now subcategorized into 12 to 15 distinct groups, each necessitating specific treatment strategies. This is crucial since therapies effective for one subgroup could potentially harm another.

In terms of genetic research, the landscape has changed dramatically since the Human Genome Project, which took 15 years and cost $3.2 billion to complete. Today, sequencing a genome could soon cost as little as $100, accelerating the ability of oncologists to utilize this critical information in the treatment process. The use of genome testing for cancer in India is booming, growing from approximately 5,000 to 200,000 tests per year in recent years, and it’s expected to reach 300,000 soon.

Confronting the Challenges in Precision Oncology

Despite these advancements, several obstacles remain in the realm of precision oncology in India. Limited awareness about advanced treatment options persists, particularly among oncologists in smaller cities, who may still adhere to traditional chemotherapy. Furthermore, many effective drugs often face availability issues or are simply too costly for the average patient. Treatments such as immunotherapy can range from ₹2.5 lakh to ₹3 lakh per cycle, requiring multiple procedures that strain personal finances.

Goswami emphasized the importance of increasing awareness among both healthcare providers and patients, paired with efforts to reduce the costs associated with these new technologies.

Integrating AI to Enhance Treatment Efficacy

4baseCare is fundamentally changing the treatment paradigm by employing artificial intelligence across its operations. This includes using AI algorithms to analyze vast data sets and generate precise treatment recommendations for oncologists and patients alike.

The startup has also received government support to create 3D tumor models in laboratory settings. These innovative models are designed to evaluate how different drugs affect tumor tissues, with the data being employed to refine AI algorithms that predict the most effective treatments for specific patient profiles.

Additionally, Goswami introduced the concept of the CG Twin—clinical genomic digital twins of cancer patients. This groundbreaking method integrates clinical and genomic data to provide a comprehensive picture of the patient’s condition. By comparing new patients with existing profiles, healthcare providers can gain insights into the most effective treatment regimens based on real-world outcomes.

Currently, the CG Twin model, backed by over 15,000 genomic tests, is undergoing trials with physicians and is anticipated to launch soon.

A Continued Commitment to Innovation in Cancer Care

The name "4baseCare" symbolizes the four DNA bases, drawing a parallel with the four essential pillars of comprehensive cancer care: allied care, technological advancement, global genomic research, and clinical practice. The goal of 4baseCare is to unify these elements, similar to how DNA operates, to foster superior cancer treatment methodologies.

Partnerships with respected hospital networks such as Apollo Hospitals, Fortis Healthcare, and Tata Memorial Centre have provided a broader platform for the startup's innovative solutions. Goswami acknowledged the challenges they faced, from securing funding to educating stakeholders about the complexities of genomics.

Yet, the vision and belief from investments such as those from Yali and Infosys have reinvigorated their mission. Motivated by the profound impact their work has on patients—like those once diagnosed with salivary gland cancer and now leading healthy lives—Goswami and his team remain dedicated to their vision.

“With every sample we handle, there’s the potential to transform lives,” Goswami concluded. “Each team member plays a crucial role in this journey, impacting families in ways they may never fully understand.”

As 4baseCare forges ahead, the intersection of genomics, AI, and compassionate care has the potential to redefine cancer treatment in India.